The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Industry s Direct’s proprietary databases, Firms ’s corporate website, SEC filings, investor presentations and featured press releases, both from industry player and market -specific third party sources, put together by Global Industry s Direct’s team.

Scope of the Research

- Keio University - Brief industry player overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Keio University human therapeutic division.
- Detailed Analysis of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Keio University with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Keio University’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Evaluate Keio University’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Keio University in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Keio University’s Research and Development portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Keio University.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Keio University and identify potential opportunities in those areas.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Keio University Snapshot 5
Key Information 5
Key Facts 5
Keio University - Research and Development Overview 6
Key Therapeutic Areas 6
Keio University - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Combination Treatment Modalities 11
Keio University - Pipeline Products Glance 12
Keio University Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 14
Keio University - Drug Profiles 15
Amrubicin 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
CPT-11 + S-1 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Cyclophosphamide + Cytarabine + Radiation Therapy + Cord Blood Transplantation 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Granulocyte-Colony Stimulating Factor 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
MAB Therapy 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
MAB Therapy + Zoledronic Acid 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
Pegylated Liposomal Doxorubicin + Carboplatin 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
TS-1 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
TS-1 + Gemcitabine 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
Urinastatin 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Keio University - Pipeline Analysis 26
Keio University - Pipeline Products by Therapeutic Class 26
Keio University Pipeline Products By Target 28
Keio University - Pipeline Products by Route of Administration 30
Keio University - Pipeline Products by Molecule Type 31
Keio University - Dormant Projects 32
Keio University - Locations And Subsidiaries 33
Head Office 33
Financial Deals Landscape 33
Keio University, Deals Summary, 2004 to 2010 33
Keio University Detailed Deal Summary 34
Yamanouchi Pharmaceutical Enters Into Collaboration Agreement With Keio University 34
Appendix 35
Methodology 35
Coverage 35
Secondary Research 35
Primary Research 35
Expert Panel Validation 36
Contact Us 36
Disclaimer 36List of Tables
Keio University - Pipeline by Therapy Area and Indication, 2010 7
Keio University - Pipeline by Stage of Development, 2010 9
Keio University - Monotherapy Products in Pipeline, 2010 10
Keio University - Combination Treatment Modalities in Pipeline, 2010 11
Keio University - Phase II, 2010 12
Keio University - Phase I, 2010 14
Keio University - Pipeline By Therapeutic Class, 2010 26
Keio University - Pipeline By Target, 2010 28
Keio University - Pipeline By Route of Administration, 2010 30
Keio University - Pipeline By Molecule Type, 2010 31
Keio University - Dormant Developmental Projects, 2010 32
Keio University, Deals Summary, 2004 to 2010 33

List of Figures
Keio University - Pipeline by Therapy Area and Indication, 2010 7
Keio University - Pipeline by Stage of Development, 2010 9
Keio University - Monotherapy Products in Pipeline, 2010 10
Keio University - Combination Treatment Modalities in Pipeline, 2010 11
Keio University - Pipeline By Therapeutic Class, 2010 26
Keio University - Pipeline By Target, 2010 28
Keio University - Pipeline By Route of Administration, 2010 30
Keio University - Pipeline By Molecule Type, 2010 31

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Diagnostics and Therapeutics for HIV: Global Markets

Diagnostics and Therapeutics for HIV: Global Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

STUDY GOALS AND OBJECTIVES The aim of this report is to provide detailed market, technology and industry analyses to help readers quantify and qualify the market for products used in the treatment, testing ...

JAK and PI3K Signaling Pathway Markets

JAK and PI3K Signaling Pathway Markets

  • $ 6 650
  • Industry report
  • April 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for signal transduction therapies/inhibitors (JAK and PI3K) reached $173.5 million in 2012. This market is expected to grow to $464.5 million in 2013 and $2.2 billion ...

Therapeutics for Women%s Health: Technologies and Global Markets

Therapeutics for Women%s Health: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • May 2014
  • by BCC Research

Use this report to: - Learn about the main women's health disorders and relevant disease prevalence population. - Identify the impact of demographic, economic, and other factors that will drive future ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.